Curacle Co Ltd
KOSDAQ:365270
Curacle Co Ltd
Curacle Co., Ltd. is engaged in the business of research and experimental development on medical sciences and pharmacy. The company is headquartered in Seoul, Seoul and currently employs 39 full-time employees. The company went IPO on 2021-07-22. The firm researches and develops synthetic drugs CU06-RE, CU01, and natural drug CU03 as new drugs for intractable vascular diseases. The Company’s drugs are used for diabetic macular edema (DME), diabetic nephropathy (DN), and wet age-related macular degeneration (wet AMD). In addition, the Company uses the SOLVADYS platform technology, a platform technology for the development of vascular endothelial dysfunction blockers.
Curacle Co., Ltd. is engaged in the business of research and experimental development on medical sciences and pharmacy. The company is headquartered in Seoul, Seoul and currently employs 39 full-time employees. The company went IPO on 2021-07-22. The firm researches and develops synthetic drugs CU06-RE, CU01, and natural drug CU03 as new drugs for intractable vascular diseases. The Company’s drugs are used for diabetic macular edema (DME), diabetic nephropathy (DN), and wet age-related macular degeneration (wet AMD). In addition, the Company uses the SOLVADYS platform technology, a platform technology for the development of vascular endothelial dysfunction blockers.